{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:46:35Z","timestamp":1791477995881,"version":"4.3.4"},"reference-count":110,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijantimicag.2025.107705","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:48:57Z","timestamp":1767804537000},"page":"107705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetics and pharmacodynamics of bacteriophage therapy: A scoping review"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7478-2269","authenticated-orcid":false,"given":"Andrew T","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-0580","authenticated-orcid":false,"given":"Nicita","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8794-4242","authenticated-orcid":false,"given":"KaiLan","family":"Mackey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3399-9637","authenticated-orcid":false,"given":"Thomas","family":"Cummiskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward K.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9718-1797","authenticated-orcid":false,"given":"Jason","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2025.107705_bib0001","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0002","unstructured":"World Health Organization. Antimicrobial resistance. WHO fact sheet. 2023."},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0003","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0004","first-page":"1193","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0005","series-title":"Antibiotic Resistance Threats in the United States, 2019","year":"2019"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0006","first-page":"17","article-title":"Tackling drug-resistant infections globally: final report and recommendations","author":"O\u2019Neill","year":"2016","journal-title":"Rev Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0007","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"400","author":"Ikuta","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00066-18","article-title":"Phage therapy in the postantibiotic era","volume":"32","author":"Gordillo Altamirano","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0009","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1128\/mr.56.3.430-481.1992","article-title":"Bacteriophage lysis: mechanism and regulation","volume":"56","author":"Young","year":"1992","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0010","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0011","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.tim.2018.09.006","article-title":"Engineering bacteriophages as versatile biologics","volume":"27","author":"Kilcher","year":"2019","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0012","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1093\/cid\/ciac453","article-title":"Phage therapy of mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease","volume":"76","author":"Dedrick","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0013","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0966-842X(00)01705-4","article-title":"Phages will out: strategies of host cell lysis","volume":"8","author":"Young","year":"2000","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0014","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cmi.2023.01.021","article-title":"Pharmacokinetics\/pharmacodynamics of phage therapy: a major hurdle to clinical translation","volume":"29","author":"Nang","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/MMBR.00012-19","article-title":"Pharmacologically aware phage therapy: pharmacodynamic and pharmacokinetic obstacles to phage antibacterial action in animal and human bodies","volume":"83","author":"D\u0105browska","year":"2019","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0016","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/antibiotics10050556","article-title":"Clinical pharmacology of bacteriophage therapy: a focus on multidrug-resistant Pseudomonas aeruginosa infections","volume":"10","author":"Holger","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0017","doi-asserted-by":"crossref","unstructured":"Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI Manual for Evidence Synthesis. JBI; 2024. Available from: https:\/\/synthesismanual.jbi.global. https:\/\/doi.org\/10.46658\/JBIMES-24-01.","DOI":"10.46658\/JBIMES-24-01"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121362","article-title":"Exploring the potential efficacy of phage therapy for biocontrol of foodborne pathogenic extensively-drug resistant Escherichia coli in gastrointestinal tract of rat model","volume":"315","author":"Abdelaziz","year":"2023","journal-title":"Life Sci"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0019","first-page":"2782","article-title":"Bacteriophage therapy increases complement-mediated lysis of bacteria and enhances bacterial clearance after a single dose of phage in mice infected with multidrug-resistant Pseudomonas aeruginosa","volume":"10","author":"Abd El-Aziz","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jgar.2019.09.018","article-title":"Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model","volume":"21","author":"Anand","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0021","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2217\/fmb-2022-0107","article-title":"Bacteriophage therapy for Escherichia coli-induced urinary tract infection in rats","volume":"18","author":"Bhargava","year":"2023","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0022","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1128\/AAC.49.7.2874-2878.2005","article-title":"Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy","volume":"49","author":"Bruttin","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0023","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/s41598-018-37636-x","article-title":"Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model","volume":"9","author":"Cafora","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0024","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1093\/cid\/ciaa705","article-title":"Phage therapy for limb-threatening prosthetic knee Klebsiella pneumoniae infection: case report and In vitro characterization of anti-biofilm activity","volume":"73","author":"Cano","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0025","first-page":"1705","article-title":"Bacteriophage therapy of experimental Vibrio vulnificus septicemia in mice","volume":"11","author":"Cerveny","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0026","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.cmi.2022.01.006","article-title":"The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice","volume":"28","author":"Chang","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0027","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3389\/fmicb.2017.00837","article-title":"The bacteriophage EF-P29 efficiently protects against lethal vancomycin-resistant Enterococcus faecalis and alleviates gut microbiota imbalance in a","volume":"8","author":"Cheng","year":"2017","journal-title":"Murine Bacteremia Model Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0028","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fmicb.2018.00561","article-title":"Liposome entrapment of bacteriophages improves wound healing in a diabetic mouse MRSA","volume":"9","author":"Chhibber","year":"2018","journal-title":"Infect Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0029","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1099\/jmm.0.2008\/002873-0","article-title":"Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice","volume":"57","author":"Chhibber","year":"2008","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02146-16","article-title":"Transfersomal phage cocktail is an effective treatment against methicillin-resistant Staphylococcus aureus-mediated skin and soft tissue infections","volume":"61","author":"Chhibber","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0031","article-title":"Pharmacokinetics and time-kill study of inhaled antipseudomonal bacteriophage therapy in mice","volume":"65","author":"Chow","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0032","article-title":"Pharmacokinetics and safety evaluation of intravenously administered Pseudomonas phage in mouse model","volume":"11","author":"Dai","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110825","article-title":"In vivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacy","volume":"39","author":"Delattre","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.684704","article-title":"Pharmacokinetics and pharmacodynamics of a novel virulent Klebsiella phage Kp_Pokalde_002 in a mouse model","volume":"11","author":"Dhungana","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0035","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3390\/antibiotics10080946","article-title":"Successful intratracheal treatment of phage and antibiotic combination therapy of a multi-drug resistant Pseudomonas aeruginosa murine model","volume":"10","author":"Duplessis","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0036","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41564-019-0634-z","article-title":"Westmead Bacteriophage Therapy Team. Safety of bacteriophage therapy in severe Staphylococcus aureus infection","volume":"5","author":"Fabijan","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0037","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/antibiotics10091048","article-title":"Topically applied bacteriophage to control multi-drug resistant Klebsiella pneumoniae infected wound in a rat model","volume":"10","author":"Fayez","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047742","article-title":"Pseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administration","volume":"7","author":"Fukuda","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0039","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1128\/AAC.01630-05","article-title":"Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle","volume":"50","author":"Gill","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0040","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1111\/bph.15526","article-title":"Inhaled bacteriophage therapy in a porcine model of pneumonia caused by Pseudomonas aeruginosa during mechanical ventilation","volume":"178","author":"Guillon","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0041","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1128\/AAC.48.10.3817-3822.2004","article-title":"Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage","volume":"48","author":"Hagens","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0042","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14041","article-title":"Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug-resistant Burkholderia multivorans","volume":"25","author":"Haidar","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0043","first-page":"14","article-title":"Phage-based therapeutics: a new weapon against multi-drug resistant bacteria","volume":"60","author":"Hodyra-Stefaniak","year":"2019","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0044","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1128\/AAC.01123-10","article-title":"Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice","volume":"55","author":"Hung","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0045","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cmi.2020.04.039","article-title":"Pharmacokinetics\/pharmacodynamics of antipseudomonal bacteriophage therapy in rats: a proof-of-concept study","volume":"26","author":"Lin","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0046","first-page":"35","article-title":"Phage therapy in a rat model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa","volume":"60","author":"Liu","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0047","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1128\/AAC.01028-06","article-title":"Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model","volume":"51","author":"McVay","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0048","article-title":"Kinetics of targeted phage rescue in a mouse model of systemic Escherichia coli K1","volume":"13","author":"Schneider","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0049","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01879-21","article-title":"Phage activity against planktonic and biofilm Staphylococcus aureus periprosthetic joint infection isolates","volume":"66","author":"Totten","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0050","first-page":"365","article-title":"Characterization of lytic enzyme open reading frame 1 (ORF1) derived from phage phi11 infecting Staphylococcus aureus","volume":"146","author":"Uchiyama","year":"2009","journal-title":"J Biochem"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0051","article-title":"Pharmacokinetics and safety evaluation of intravenously administered Pseudomonas phage in mouse model","volume":"14","author":"Wang","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0052","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/v11010010","article-title":"Interactions between bacteriophage, bacteria, and the mammalian immune system","volume":"11","author":"Van Belleghem","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0053","doi-asserted-by":"crossref","first-page":"eaat9691","DOI":"10.1126\/science.aat9691","article-title":"Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection","volume":"363","author":"Sweere","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0054","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/imr.12565","article-title":"A bacteriophage journey through the human body","volume":"279","author":"Barr","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0055","article-title":"Pharmacokinetics and biodistribution of phages and their current applications in antimicrobial therapy","volume":"7","author":"Kang","year":"2023","journal-title":"Adv Ther (Weinh)"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0056","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/med.21572","article-title":"Phage therapy: what factors shape phage pharmacokinetics and bioavailability? Systematic and critical review","volume":"39","author":"D\u0105browska","year":"2019","journal-title":"Med Res Rev"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0057","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00044-24","article-title":"Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant gram-negative bacterial infections","volume":"37","author":"Siopi","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0058","article-title":"Pharmacokinetics and biodistribution of phages and their current applications in antimicrobial therapy","volume":"7","author":"Kang","year":"2024","journal-title":"Adv Ther (Weinh)"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0059","first-page":"1601","article-title":"Pharmacokinetic and pharmacodynamic obstacles for phage therapy from the perspective of clinical practice","volume":"12","author":"Mi\u0119dzybrodzki","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0060","article-title":"The contribution of neutrophils to bacteriophage clearance and pharmacokinetics in vivo","volume":"9","author":"Bachmann","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0061","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01874-17","article-title":"Bacteriophage transcytosis provides a mechanism to cross epithelial cell layers","volume":"8","author":"Nguyen","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0062","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.virusres.2005.05.014","article-title":"An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold","volume":"114","author":"Vitiello","year":"2005","journal-title":"Virus Res"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0063","first-page":"151","article-title":"Immunological factors that affect the in vivo fate of T7 phage in the mouse","volume":"64","author":"Srivastava","year":"2004","journal-title":"Antivir Res"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0064","article-title":"Purely polysaccharide-based biofilm matrix provides size-selective diffusion barriers for nanoparticles and bacteriophages","volume":"38","author":"Dunsing","year":"2019","journal-title":"EMBO J"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0065","first-page":"545","article-title":"Charge influences penetration of mucus matrices and diffusion in human cystic fibrosis sputum","volume":"6","author":"Lieleg","year":"2010","journal-title":"Soft Matter"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0066","first-page":"1019","article-title":"Phage types and their characteristics","volume":"71","author":"Jo\u0144czyk-Matysiak","year":"2017","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0067","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1128\/AEM.00812-15","article-title":"Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp","volume":"81","author":"Colom","year":"2015","journal-title":"Appl Env Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0068","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1128\/AEM.02304-07","article-title":"Fluorescence correlation spectroscopy to study diffusion and reaction of bacteriophages inside biofilms","volume":"74","author":"Briandet","year":"2008","journal-title":"Appl Env Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0069","first-page":"291","article-title":"Bacteriophage penetration of bacterial biofilms: an in vitro study","volume":"17","author":"Corbin","year":"2001","journal-title":"Biofouling"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0070","first-page":"117","article-title":"Diffusion of phages through biofilms","volume":"9","author":"Doolittle","year":"1995","journal-title":"Biofouling"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0071","first-page":"131","article-title":"Diffusion of bacteriophages through artificial biofilm models","volume":"54","author":"Ganesh","year":"2014","journal-title":"J Basic Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0072","doi-asserted-by":"crossref","first-page":"11197","DOI":"10.1073\/pnas.0704624104","article-title":"Dispersing biofilms with engineered enzymatic bacteriophage","volume":"104","author":"Lu","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0073","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/08927010400010494","article-title":"Solute size effects on the diffusion in biofilms of Streptococcus mutans","volume":"20","author":"Marcotte","year":"2004","journal-title":"Biofouling"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0074","first-page":"4141","article-title":"Nondestructive cryopreservation of bacterial biofilms using fluorescently labeled bacteriophages","volume":"74","author":"Pearl","year":"2008","journal-title":"Appl Env Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0075","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.chom.2015.10.013","article-title":"Filamentous bacteriophage promote biofilm assembly and function","volume":"18","author":"Secor","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0076","first-page":"45","article-title":"Phage diffusion in biofilms: a quantitative approach","volume":"26","author":"Sillankorva","year":"2010","journal-title":"Biofouling"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0077","doi-asserted-by":"crossref","DOI":"10.1038\/srep14802","article-title":"Mammalian host-versus-phage immune response determines phage fate in vivo","volume":"5","author":"Hodyra-Stefaniak","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2017.06.018","article-title":"Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen","volume":"22","author":"Roach","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.04.024","article-title":"Host and pathogen response to bacteriophage engineered against mycobacterium abscessus lung infection","volume":"185","author":"Nick","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0080","first-page":"726","article-title":"Bacteriophage therapy for difficult-to-treat infections: the implementation of a multidisciplinary phage task force","volume":"30","author":"Bichet","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0081","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02071-21","article-title":"Considerations for the use of phage therapy in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0082","article-title":"Phage\u2013antibody conjugates for the treatment of multidrug-resistant Pseudomonas aeruginosa keratitis","volume":"226","author":"Liu","year":"2023","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0083","first-page":"1067","article-title":"Deconstructing the phage\u2013Bacterial biofilm interaction as a basis to establish new antibiofilm strategies","volume":"14","author":"Gonz\u00e1lez","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0084","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/antibiotics11050616","article-title":"Salvage bacteriophage therapy for recalcitrant MRSA prosthetic joint infection","volume":"11","author":"Doub","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0085","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/antibiotics11050616","article-title":"Salphage: salvage bacteriophage therapy for recalcitrant MRSA prosthetic joint infection","volume":"11","author":"Doub","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0086","article-title":"Lyon BJI Study Group. Phage therapy as adjuvant to conservative surgery and antibiotics to salvage patients with relapsing S. aureus prosthetic knee infection","volume":"7","author":"Ferry","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0087","doi-asserted-by":"crossref","DOI":"10.5694\/mja2.50274","article-title":"Adjunctive bacteriophage therapy for prosthetic valve endocarditis due to Staphylococcus aureus","volume":"211","author":"Gilbey","year":"2019","journal-title":"Med J Aust"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0088","article-title":"Pulmonary bacteriophage and cystic fibrosis airway mucus: friends or foes?","volume":"10","author":"Sahota","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0089","article-title":"Phage therapy for Respiratory infections: opportunities and challenges","volume":"258","author":"Chang","year":"2024","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0090","first-page":"15","article-title":"The potential of phage therapy in cystic fibrosis: essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways","volume":"123","author":"Tariq","year":"2017","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0091","first-page":"1328","article-title":"The challenges of phage therapy in respiratory infections","volume":"13","author":"Dufour","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0092","first-page":"1558","article-title":"Bacteriophage therapy as a focused management strategy in post-operative joint infection caused by Staphylococcus aureus: a narrative review","volume":"28","author":"Prazak","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0093","article-title":"Phage therapy dosing: the problem of source and site","volume":"3","author":"Abedon","year":"2013","journal-title":"Bacteriophage"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0094","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cis.2017.05.014","article-title":"Formulation, stabilisation and encapsulation of bacteriophage for phage therapy","volume":"249","author":"Malik","year":"2017","journal-title":"Adv Colloid Interface Sci"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0095","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.2042-7158.2011.01324.x","article-title":"Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy","volume":"63","author":"Ryan","year":"2011","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0096","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-0716-3523-0_10","article-title":"Studying bacteriophage efficacy using a zebrafish model","volume":"2734","author":"Cafora","year":"2024","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0097","doi-asserted-by":"crossref","DOI":"10.1128\/AEM.01979-20","article-title":"Encapsulation and delivery of therapeutic phages","volume":"87","author":"Loh","year":"2021","journal-title":"Appl Env Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0098","first-page":"1095","article-title":"Bacteriophage therapy for difficult-to-treat infections: the implementation of a multidisciplinary phage task force (The PHAGEFORCE study protocol)","volume":"21","author":"Onsea","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102287","article-title":"Bacteriophage uptake by mammalian cell layers represents a potential sink that may impact phage therapy","volume":"24","author":"Bichet","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0100","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00018-004-4403-6","article-title":"The potential role of endogenous bacteriophages in controlling invading pathogens","volume":"62","author":"G\u00f3rski","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0101","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00003088-200342040-00002","article-title":"Pharmacokinetic principles of bacteriophage therapy","volume":"42","author":"Abedon","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0102","article-title":"Differential translocation of bacteriophages across the intestinal barrier in health and Crohn\u2019s disease","volume":"44","author":"Douadi","year":"2025","journal-title":"Cell Rep"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0103","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02071-21","article-title":"Considerations for the use of phage therapy in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0104","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1751-7915.2008.00028.x","article-title":"PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response","volume":"1","author":"Kim","year":"2008","journal-title":"Microb Biotechnol"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0105","first-page":"3433","article-title":"Plasma clearance of bacteriophage qbeta particles as a function of surface charge","volume":"283","author":"Singaravelu","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0106","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/mp3003754","article-title":"Biodistribution and pharmacokinetics of chemically modified bacteriophage MS2 in mice","volume":"10","author":"Chen","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0107","first-page":"652","article-title":"Deletion of the Hoc and Soc capsid proteins affects the surface and cellular uptake properties of bacteriophage T4 derived nanoparticles","volume":"422","author":"Li","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0108","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1016\/j.csbj.2021.06.001","article-title":"Structural and functional characterization of the receptor binding proteins of Escherichia coli O157 phages EP75 and EP335","volume":"19","author":"Witte","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0109","article-title":"Bacteriophage specificity is impacted by interactions between bacteria","volume":"9","author":"Scanlan","year":"2024","journal-title":"mSystems"},{"key":"10.1016\/j.ijantimicag.2025.107705_bib0110","article-title":"Pharmacokinetics and time-kill study of inhaled antipseudomonal bacteriophage therapy in mice","volume":"65","author":"Chow","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925002602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925002602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T14:33:48Z","timestamp":1779460428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857925002602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0924857925002602"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107705","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and pharmacodynamics of bacteriophage therapy: A scoping review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107705"}}